Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...
Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...
Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
402 Index<br />
leukemia<br />
±, acute lymphocytic 302<br />
±, acute myelocytic 302, 305f.<br />
±, B cell 362<br />
±, chronic myelogenous 301ff.<br />
±, chronic myeloid 189<br />
±, hairy cell 362<br />
±, immunotoxins 361f.<br />
±, T cell 347, 362<br />
LeY see carbohydrate antigen Lewis Y<br />
LFA-2 326<br />
life cycle, of dendritic cells 185<br />
lipids, cationic 274<br />
lipopolysaccharides (LPSs), bacterial<br />
immunotherapy 269, 271f., 273<br />
liver metastases, immunocytokines 337f.<br />
LLC-CEA-KSA 324, 327<br />
LMB2 see anti-Tac(Fv)-PE38<br />
LMB7 <strong>and</strong> LMB9, immunotoxins 360<br />
LMP2, LMP7 see b subunits of 20S<br />
proteasome<br />
LOH see loss of heterozygosity<br />
loss<br />
±, antigen 66±69, 72±76, 331<br />
±, of heterozygosity (LOH), MHC class I 67,<br />
74f.<br />
low-affinity CTL responses 194<br />
low-affinity receptor for the nerve growth factor<br />
(DNGER) 304f.<br />
low-avidity TCR 232<br />
LPS see lipopolysaccharides<br />
LT-a see lymphotoxin (LT)-a<br />
lymphocyte migration, T bodies 295<br />
lymphoid CD123 DCs 180f.<br />
lymphoid-derived DCs 105<br />
lymphoid-like tissues, peripheral 333f.<br />
lymphokine-activated killer (LAK)<br />
±, effects of prostagl<strong>and</strong>in (PG) E2 132<br />
±, effects of TGF-b 123<br />
lymphoma<br />
±, B cell 347<br />
±, Hodgkin lymphomas 163<br />
±, immunotoxins 361f.<br />
±, non-Hodgkin lymphomas (NHL) 163,<br />
189<br />
lymphotoxin (LT)-a, tumor targeting 333f.<br />
lymphotoxin (LT)-a fusion proteins 313<br />
lymphotoxin (LT)-a immunocytokine 333f.<br />
lysis, hTERT specific see cytolysis<br />
m<br />
mAb B3 360f., 367<br />
mAb e23 360f.<br />
mAbs see monoclonal antibodies<br />
macrophage migration inhibitory factor<br />
(MIF) 120, 130<br />
macrophages<br />
±, effects of IL-10 126, 158f.<br />
±, effects of polyamines 133f.<br />
±, effects of prostagl<strong>and</strong>in (PG) E2 131<br />
±, effects of TGF-b 121<br />
±, tumor cell killing 218<br />
±, tumor microenvironment 107f., 113<br />
MAGE see melanoma antigens<br />
maintenance therapy, HCV 240f.<br />
major histocompatibility complex (MHC) 3,<br />
6 ff., 30, 44, 52, 59±94, 210<br />
MAPKs see mitogen-activated protein kinases<br />
matrix metalloproteinases (MMPs) 110<br />
±, effects of IL-10 165<br />
maturation<br />
±, dendritic cells 181, 185±187<br />
MDA see melanoma differentiation associated<br />
gene<br />
melanoma<br />
±, clinical trials 189, 193<br />
±, HCV 239f.<br />
±, immunocytokines 330±336<br />
melanoma antigens (MAGE) 19, 26<br />
±, CTL monitoring 45±50<br />
±, immunotoxins 365<br />
melanoma differentiation associated gene<br />
(MDA)-7 157<br />
melanoma metastases, treatment with<br />
immunocytokines 330ff.<br />
memory responses 195<br />
memory T cells, immunocytokines 317<br />
mesothelin 361<br />
metalloproteinases<br />
±, inhibitors 113<br />
±, matrix 110<br />
metastases<br />
±, liver 337f.<br />
±, melanoma 330ff.<br />
methylation of cytosines, bacterial immunotherapy<br />
269<br />
MHC see major histocompatibility complex<br />
MHC antigens<br />
±, expression determination 63f.<br />
±, HSPs 263<br />
MHC class I alterations<br />
±, impact on immuneresponses <strong>and</strong> clinical<br />
relevance 76±79<br />
±, underlying molecular mechanisms<br />
66±76<br />
MHC class I antigen<br />
±, immunocytokines 316, 321, 326f., 334f.<br />
±, immunotoxins 365
Change language